ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Immunotherapy-focused Cue Biopharma launches

by Lisa M. Jarvis
January 30, 2017 | APPEARED IN VOLUME 95, ISSUE 5

Cue Biopharma has emerged from stealth with $26 million in funding to develop T-cell receptor-targeted biologics. Founded in 2015 with $10 million in seed funding, Cue hopes to tackle cancer and autoimmune diseases by developing biologics that will modulate the activity of specific sets of T cells. By outfitting an antibody with both an engineered T-cell signaling ligand and a peptide complex specific for disease-relevant T cells, Cue can elicit a highly specific response, either stimulating T cells to combat cancer or dampening the T-cell response in autoimmune diseases. The biotech firm has two drug candidates in preclinical studies for cancer.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment